Telomir says Ohio State research shows Telomir-Zn inhibits growth in human, canine osteosarcoma cell lines
TELO•Ohio State research on Telomir-Zn
Telomir Pharmaceuticals disclosed in-vitro research with Ohio State showing Telomir-Zn inhibited growth in human and canine osteosarcoma models.
Results were presented in the announcement, not slated for a future conference readout.
Potential follow-on study and lead program
Management signaled a potential in vivo canine osteosarcoma study, positioning it as a translational path toward human osteosarcoma development.
Primary near-term focus remains its triple-negative breast cancer program, moving toward site initiation for Phase 1/2 enrollment under an FDA-cleared IND.
The update broadens optionality for Telomir-Zn, potentially supporting multiple oncology indications while the lead TNBC program advances.
